Bio-engineered strain of E. coli targets drug-resistant Pseudomonas aeruginosa

---

Study: Biotech strain of E. coli targets drug-resistant P. aeruginosa

16 August 2011


"Singaporean scientists said they have developed a bioengineered strain of E. coli bacteria that proved effective in stopping the growth of Pseudomonas aeruginosa, a drug-resistant microbe usually found in hospitals, by 90%.

The biotech E. coli works by producing and releasing a toxin that targets the pathogen, the scientists reported in the journal Molecular Systems Biology. 

The formula used to re-engineer the bacteria could be used to bioengineer other microbes against infectious pathogens, said the lead author of the study."

Reuters article:

http://www.reuters.com/article/2011/08/16/us-bacteria-singapore-bug-idUSTRE77F35B20110816


Original source:

http://www.nature.com/msb/journal/v7/n1/full/msb201155.html

---

http://www.nature.com/msb/index.html

-------------------

Posted 18 Aug 2011 by:

David A. Palella
BIOSCIENCE VENTURES Inc.

San Diego, California
cell: 619-787-5767
email:  dpalella@gmail.com
http://www.linkedin.com/in/davidpalella

web site:  http://www.BSVpartners.com

blog: http://biobizdev.blogspot.com


& Group Founder:

Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/

Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/

Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/

Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/

& Co-founder:

Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448


--------